An evaluation of the tissue distribution and the selective tumor trafficking of TNF [tumour necrosis factor]-bound colloidal gold (CYT-6091) following intravenous administration in subjects with primary and metastatic cancer undergoing surgical resection.

Trial Profile

An evaluation of the tissue distribution and the selective tumor trafficking of TNF [tumour necrosis factor]-bound colloidal gold (CYT-6091) following intravenous administration in subjects with primary and metastatic cancer undergoing surgical resection.

Completed
Phase of Trial: Phase 0

Latest Information Update: 01 May 2012

At a glance

  • Drugs CYT 6091 (Primary)
  • Indications Adrenal cancer; Breast cancer; Colorectal cancer; Gastrointestinal cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cancer; Sarcoma
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 May 2012 Trial phase changed from I to 0 as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top